Cosmetic cross-reference Noindex: medium evidence

Salnacedin

CAS 87573-01-1

Salnacedin (CAS 87573-01-1) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral / FAERS
Adverse signals
0
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Salnacedin
CAS Number
87573-01-1
UNII
02X9QIP2NU
InChIKey
VYPKEODFNOEZGS-VIFPVBQESA-N
ChEMBL ID
CHEMBL2106981
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL2106981 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Salnacedin used for in pharmaceutical contexts?

Salnacedin (CAS 87573-01-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Salnacedin?

No adverse-event association or SIDER side-effect rows are rendered for Salnacedin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Salnacedin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Salnacedin with EU status "permitted".

What clinical phase is Salnacedin in?

Salnacedin is rendered with ChEMBL max phase 2.